DRUG_NAME,STRUCT_ID,TARGET_NAME,TARGET_CLASS,ACCESSION,GENE,SWISSPROT,ACT_VALUE,ACT_UNIT,ACT_TYPE,ACT_COMMENT,ACT_SOURCE,RELATION,MOA,MOA_SOURCE,ACT_SOURCE_URL,MOA_SOURCE_URL,ACTION_TYPE,TDL,ORGANISM,NEW_ID
adenosine triphosphate,91,Heat shock cognate 71 kDa protein,Unclassified,P11142,HSPA8,HSP7C_HUMAN,4.76,,IC50,PUBCHEM_BIOASSAY: In Vitro Hsc70 Dose Response Fluorescence Polarization Assay. (Class of assay: confirmatory) [Related pubchem assays: 1072 ],CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5241
adenosine triphosphate,91,Heat shock 70 kDa protein 1A,Unclassified,P0DMV8,HSPA1A,HS71A_HUMAN,5.47,,IC50,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5232
amodiaquine,186,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,5.4,,IC50,Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
anileridine,220,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201347,AGONIST,Tclin,Homo sapiens,HGNC:8156
aprindine,231,Calmodulin,Cytosolic other,P0DP23|P0DP24|P0DP25,CALM1|CALM2|CALM3,CALM1_HUMAN|CALM2_HUMAN|CALM3_HUMAN,4.745,,ID50,,WOMBAT-PK,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/6186851,INHIBITOR,Tclin|Tclin|Tclin,Homo sapiens,HGNC:1442
butorphanol,454,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.92,,Ki,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL33986,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
carmofur,511,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.213,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
carvedilol,522,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.52,,IC50,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
cinnarizine,654,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.035,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
codeine,725,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.14,,Ki,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL485,AGONIST,Tclin,Homo sapiens,HGNC:8156
dactinomycin,774,Growth factor receptor-bound protein 2,Cytosolic other,P62993,GRB2,GRB2_HUMAN,5.3,,IC50,Inhibition of GST-Grb2 Tyrosine kinase SH2 domain binding to [3H]labeled-phosphopeptide (Ac-SpYVNK-NH-C(O)-CH2CH2H3),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:4566
dactinomycin,774,Growth factor receptor-bound protein 2,Cytosolic other,Q60631,Grb2,GRB2_MOUSE,5.3,,IC50,In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined,CHEMBL,=,,,,,,,Mus musculus,MGI:95805
dextropropoxyphene,844,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213351,AGONIST,Tclin,Homo sapiens,HGNC:8156
dextrothyroxine,846,Glutamate NMDA receptor,Ion channel,P35439|Q00959|Q00960|Q00961|Q62645|Q8VHN2|Q9R1M7,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,NMDZ1_RAT|NMDE1_RAT|NMDE2_RAT|NMDE3_RAT|NMDE4_RAT|NMD3B_RAT|NMD3A_RAT,6.48,,IC50,Ability to displace [3H]L-689560 from NMDA receptor glycine site in rat brain membranes,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:2736
dezocine,847,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.42,,EC50,Agonist activity at human cloned mu opioid receptor by [35S]GTPgammaS binding assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1685,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
diacerein,849,Caspase-3,Enzyme,P42574,CASP3,CASP3_HUMAN,5.1,,EC50,"PUBCHEM_BIOASSAY: Absorbance-based biochemical high throughput dose response assay for activators of procaspase-3. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463141, AID463197, AID463210, AID488941, AID488954, AID493114, AID493115, AID504328, AID504330]",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:1504
difenoxin,878,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action; CHEMBL233; SINGLE PROTEIN,CHEMBL,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201321,AGONIST,Tclin,Homo sapiens,HGNC:8156
alpha-Ergocryptine,885,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.007,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
dihydrocodeine,886,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action; CHEMBL233; SINGLE PROTEIN,CHEMBL,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1595,AGONIST,Tclin,Homo sapiens,HGNC:8156
dihydroergocristine,887,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.462,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
diphenoxylate,918,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.167,,IC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201294,AGONIST,Tclin,Homo sapiens,HGNC:8156
docetaxel,939,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.086,,Kd,,WOMBAT-PK,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
docetaxel,939,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,6.699,,ID50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545252,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
domperidone,945,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.766,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
domperidone,945,Calmodulin,Cytosolic other,P0DP23|P0DP24|P0DP25,CALM1|CALM2|CALM3,CALM1_HUMAN|CALM2_HUMAN|CALM3_HUMAN,,,,,WOMBAT-PK,,,,,,,Tclin|Tclin|Tclin,Homo sapiens,HGNC:1442
everolimus,1118,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,8.7,,IC50,,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3942
felbamate,1140,"Glutamate receptor ionotropic, NMDA 2B",Ion channel,Q13224,GRIN2B,NMDE2_HUMAN,4.284,,IC50,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1094,ANTAGONIST,Tclin,Homo sapiens,HGNC:4586
formoterol,1239,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,8.523,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
glycine,1319,"Glutamate receptor ionotropic, NMDA 1",Ion channel,P35439,Grin1,NMDZ1_RAT,6.6,,IC50,In vitro inhibitory activity to inhibit [3H]glycine binding to NMDA receptor,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:2736
glycine,1319,Glutamate NMDA receptor,Ion channel,P35439|Q00959|Q00960|Q00961|Q62645|Q8VHN2|Q9R1M7,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,NMDZ1_RAT|NMDE1_RAT|NMDE2_RAT|NMDE3_RAT|NMDE4_RAT|NMD3B_RAT|NMD3A_RAT,6.77,,Ki,"Affinity for the glycine binding site of NMDA receptor by inhibition of [3H]5,7-dichlorokynurenic acid ([3H]DCKA) binding to rat brain synaptic membrane",CHEMBL,=,,,,,,,Rattus norvegicus,RGD:2736
hydrocodone,1386,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.02,,Ki,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1457,AGONIST,Tclin,Homo sapiens,HGNC:8156
hydromorphone,1393,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.55,,Ki,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL398707,AGONIST,Tclin,Homo sapiens,HGNC:8156
ixabepilone,1517,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/19010832,https://pubmed.ncbi.nlm.nih.gov/19010832,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
ketobemidone,1526,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,9.0,,EC50,,WOMBAT-PK,=,,,,,,Tclin,Homo sapiens,HGNC:8156
lansoprazole,1547,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.28,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
lapatinib,1548,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.04,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201179,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
lapatinib,1548,Tubulin alpha-1A chain,Structural,P68370,Tuba1a,TBA1A_RAT,7.27,,Kd,Binding constant for ERBB4 kinase domain,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:619717
levomethadyl acetate,1571,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1514,AGONIST,Tclin,Homo sapiens,HGNC:8156
loperamide,1599,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.824,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL841,AGONIST,Tclin,Homo sapiens,HGNC:8156
loperamide,1599,Calmodulin,Cytosolic other,P0DP23|P0DP24|P0DP25,CALM1|CALM2|CALM3,CALM1_HUMAN|CALM2_HUMAN|CALM3_HUMAN,,,,,WOMBAT-PK,,,,,,,Tclin|Tclin|Tclin,Homo sapiens,HGNC:1442
loperamide,1599,"Glutamate receptor ionotropic, NMDA 2B",Ion channel,Q13224,GRIN2B,NMDE2_HUMAN,,,,,WOMBAT-PK,,,,,,,Tclin,Homo sapiens,HGNC:4586
loperamide,1599,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,9.8,,Ki,Binding affinity for Mu opioid receptor of rat brain,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
memantine,1679,"Glutamate receptor ionotropic, NMDA 1",Ion channel,Q05586,GRIN1,NMDZ1_HUMAN,5.02,,IC50,Inhibition of NMDA NR1/NR2B receptor expressed in xenopus oocytes assessed as inhibition of NMDA and glycine-induced current response by two-electrode voltage clamp assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1699,NEGATIVE ALLOSTERIC MODULATOR,Tclin,Homo sapiens,HGNC:4584
memantine,1679,Glutamate NMDA receptor; GRIN1/GRIN2B,Ion channel,Q05586|Q13224,GRIN1|GRIN2B,NMDZ1_HUMAN|NMDE2_HUMAN,5.26,,IC50,Inhibition of dexamethasone-induced human NR1-1a/NR2B receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L13-E6 cells assessed as LDH release after 30 mins,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1699,NEGATIVE ALLOSTERIC MODULATOR,Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:4584
memantine,1679,Glutamate NMDA receptor; GRIN1/GRIN2A,Ion channel,Q05586|Q12879,GRIN1|GRIN2A,NMDZ1_HUMAN|NMDE1_HUMAN,9.02,,IC50,Antagonist activity at recombinant GluN1/GluN2A receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glycine/glutamate-induced inward current at -70mV by two-electrode voltage clamp assay,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1699,NEGATIVE ALLOSTERIC MODULATOR,Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:4584
meptazinol,1706,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.06,,EC50,,WOMBAT-PK,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/6141283,PARTIAL AGONIST,Tclin,Homo sapiens,HGNC:8156
methadone,1728,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.78,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL651,AGONIST,Tclin,Homo sapiens,HGNC:8156
acetylmethadol,1729,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,KEGG DRUG,https://pubmed.ncbi.nlm.nih.gov/19153939,http://www.kegg.jp/entry/D04973,AGONIST,Tclin,Homo sapiens,HGNC:8156
midodrine,1803,Heat shock protein HSP 90-alpha,Cytosolic other,P07900,HSP90AA1,HS90A_HUMAN,7.699,,IC50,,WOMBAT-PK,=,,,,,,Tchem,Homo sapiens,HGNC:5253
miltefosine,1810,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,5.02,,IC50,Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
montelukast,1836,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.495,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
nalbuphine,1874,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.8,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL895,AGONIST,Tclin,Homo sapiens,HGNC:8156
octreotide,1980,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.921,,Ki,,PDSP,,,,,,,Tclin,Homo sapiens,HGNC:8156
omeprazole,1990,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.47,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
ondansetron,1992,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,5.54,,Ki,The binding affinity was measured on mu-opiate receptor using [3H]- naloxone as radioligand.,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
pantoprazole,2054,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.39,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
penfluridol,2080,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.06,,Ki,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:8156
perhexiline,2106,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.828,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
phenelzine,2123,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.75,,Ki,Inhibition of LSD1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
propiram,2299,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,WOMBAT-PK,,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/7693433,AGONIST,Tclin,Homo sapiens,HGNC:8156
rabeprazole,2350,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.23,,Ki,,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
remifentanil,2363,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,,WOMBAT-PK,,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1005,AGONIST,Tclin,Homo sapiens,HGNC:8156
remifentanil,2363,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,9.22,,IC50,Displacement of [3H]DAMGO from rat brain mu opioid receptor incubated for 60 mins by microbeta scintillation counting method,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
remifentanil,2363,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,9.22,,IC50,Displacement of [3H]DAMGO from rat brain mu opioid receptor incubated for 60 mins by microbeta scintillation counting method,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
sirolimus,2446,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,10.0,,IC50,Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
sulfaethidole,2504,RAC-alpha serine/threonine-protein kinase,Kinase,P31749,AKT1,AKT1_HUMAN,5.11,,Kd,"SPR Competitive Binding Assay: SPR interaction analyses were performed with a Biacore 2000, using Biacore 2000 Control Software v3.2 and BIAevaluation v4.1 analysis software (Biacore) as described in Mol Cancer Ther 7:2621 (2008). For the competitive binding assays and the Ki determination, PtdIns(3,4,5)phosphate-biotin labeled liposomes (Echelon Biosciences) and SA chips were used with increasing concentrations of the compound tested.",CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:391
suloctidil,2536,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.1,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tacrolimus,2552,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,9.02,,IC50,Inhibitory activity against macrophilin (FKBP-12),CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
tianeptine,2650,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.417,,Ki,,PDSP,,,,,,,Tclin,Homo sapiens,HGNC:8156
tilidine,2663,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.1,,EC50,,WOMBAT-PK,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/15627429,AGONIST,Tclin,Homo sapiens,HGNC:8156
tramadol,2711,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,5.8,,Ki,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237044,AGONIST,Tclin,Homo sapiens,HGNC:8156
tramadol,2711,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,5.62,,Ki,Displacement of [3H]-dihydromorphine from mu opioid receptor in rat cerebral cortex by liquid scintillation counting,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
tranylcypromine,2715,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.6,,Ki,Inhibition of human recombinant His-tagged full length LSD1 expressed in Escherichia coli BL21 (DE3) assessed as inactivation constant preincubated for 20 mins with substrate measured after 30 mins by AmplexRed based fluorescence quenching assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
vesnarinone,2817,Transitional endoplasmic reticulum ATPase,Enzyme,P55072,VCP,TERA_HUMAN,,,,Vesnarinone binds to the D1 domain of VCP,SCIENTIFIC LITERATURE,,,,https://pubmed.ncbi.nlm.nih.gov/23393163,,,Tchem,Homo sapiens,HGNC:12666
vinorelbine,2827,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/19010832,https://pubmed.ncbi.nlm.nih.gov/19010832,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
nicotinic acid,2835,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,4.88,,IC50,Inhibition of amyloid beta aggregation (unknown origin) after 4 hrs by thioflavin S assay in absence of Zn2+,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
zafirlukast,2855,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.24,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
zafirlukast,2855,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.359,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
zotarolimus,2949,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,8.48,,IC50,Inhibitory activity against FKBP12,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
somatostatin,2997,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,8.22,,IC50,Inhibition of binding of [3H]-naloxone to Opioid receptor mu 1 of rat brain membranes,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
diosmin,3157,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.99,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
diosmin,3157,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.99,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
etoxadrol,3215,Glutamate NMDA receptor,Ion channel,P35439|Q00959|Q00960|Q00961|Q62645|Q8VHN2|Q9R1M7,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,NMDZ1_RAT|NMDE1_RAT|NMDE2_RAT|NMDE3_RAT|NMDE4_RAT|NMD3B_RAT|NMD3A_RAT,6.97,,Ki,Displacement of [3H]TCP from tissue homogenate preparation of whole rat brain minus cerebellum,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:2736
ruboxistaurin,3533,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.29,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
ruboxistaurin,3533,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,6.68,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
ruboxistaurin,3533,Casein kinase II subunit alpha,Kinase,P68400,CSNK2A1,CSK21_HUMAN,5.44,,Kd,Binding constant for full-length CSNK2A1,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:2457
sulbentine,3557,Mu-type opioid receptor,GPCR,P33535,Oprm1,OPRM_RAT,4.55,,IC50,In vitro inhibition of [3H]DAMGO (Tyr-D-Ala-Gly-(Me)-Phe-Gly-ol) binding to Opioid receptor mu 1 using rat brain membranes,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:3234
vinflunine,3644,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/19010832,https://pubmed.ncbi.nlm.nih.gov/19010832,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
ciramadol,3713,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/2572952,https://pubmed.ncbi.nlm.nih.gov/2572952,MODULATOR,Tclin,Homo sapiens,HGNC:8156
baicalin,4055,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.45,,IC50,Inhibition of LSD1 (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
baicalin,4055,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,5.45,,IC50,Inhibition of LSD1 (unknown origin),CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
tirilazad,4063,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,4.69,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tirilazad,4063,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,4.789,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
proline,4125,"Glutamate receptor ionotropic, NMDA 1",Ion channel,P35439,Grin1,NMDZ1_RAT,4.76,,IC50,Inhibitory concentration required to inhibit [3H]strychnine binding to N-methyl-D-aspartate glutamate receptor 1,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:2736
gentian violet,4138,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,6.06,,Ki,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:8156
gentian violet,4138,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.325,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cabazitaxel,4153,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,Mechanism of Action,SCIENTIFIC LITERATURE,,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/23337758,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
temsirolimus,4161,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,5.75,,IC50,Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3942
eribulin,4171,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,8.23,,IC50,,IUPHAR,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/19010832,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
vandetanib,4178,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.32,,Kd,Binding constant for EGFR(E746-A750del) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24828,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
vandetanib,4178,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,5.8,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
vandetanib,4178,Tubulin alpha-1A chain,Structural,P68370,Tuba1a,TBA1A_RAT,6.32,,Kd,Binding constant for ERBB4 kinase domain,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:619717
crizotinib,4187,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.57,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
crizotinib,4187,Inhibitor of nuclear factor kappa-B kinase subunit beta,Kinase,O14920,IKBKB,IKKB_HUMAN,5.26,,Kd,Binding constant for IKK-beta kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:5960
crizotinib,4187,Ribosomal protein S6 kinase beta-1,Kinase,P23443,RPS6KB1,KS6B1_HUMAN,6.19,,Kd,Binding constant for S6K1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:10436
crizotinib,4187,Serine/threonine-protein kinase ULK1,Kinase,O75385,ULK1,ULK1_HUMAN,6.0,,Kd,Binding constant for ULK1 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:12558
axitinib,4225,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.64,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tapentadol,4283,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,7.018,,Ki,,WOMBAT-PK,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201777,AGONIST,Tclin,Homo sapiens,HGNC:8156
Florbetapir F-18,4285,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,8.54,,Ki,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
Flutemetamol (18F),4301,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,9.15,,Ki,Binding affinity to human amyloid beta plaque,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
afatinib,4318,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,10.0,,Kd,Binding constant for EGFR(G719C) kinase domain,CHEMBL,=,1.0,CHEMBL,,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1173655,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
zinc chloride,4344,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.66,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cisplatin,4392,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.582,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cisplatin,4392,Mitogen-activated protein kinase 3,Kinase,P27361,MAPK3,MK03_HUMAN,5.335,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",DRUG MATRIX,=,,,,,,Tchem,Homo sapiens,HGNC:6877
colistin,4425,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.824,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
esketamine,4468,Glutamate NMDA receptor,Ion channel,P35439|Q00959|Q00960|Q00961|Q62645|Q8VHN2|Q9R1M7,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,NMDZ1_RAT|NMDE1_RAT|NMDE2_RAT|NMDE3_RAT|NMDE4_RAT|NMD3B_RAT|NMD3A_RAT,6.161,,Ki,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/23183107,,ANTAGONIST,,Rattus norvegicus,RGD:2736
carfilzomib,4483,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,5.84,,IC50,Inhibition of human caspase-like activity of 20S constitutive proteasome preincubated for 15 mins followed by substrate addition by fluorescence assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9537
carfilzomib,4483,Proteasome subunit beta type-2,Enzyme,P49721,PSMB2,PSB2_HUMAN,6.69,,IC50,Inhibition of 20S proteasome beta2 subunit in human Jurkat cell lysate using Suc-RLR-AMC as substrate pretreated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9539
carfilzomib,4483,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,5.84,,IC50,Inhibition of human caspase-like activity of 20S constitutive proteasome preincubated for 15 mins followed by substrate addition by fluorescence assay,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:9537
diosmetin,4601,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.55,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
diosmetin,4601,Lysine-specific histone demethylase 1A,Enzyme,O60341,KDM1A,KDM1A_HUMAN,4.55,,IC50,Inhibition of LSD1 (unknown origin) by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:29079
sodium aurothiomalate,4706,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.624,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",DRUG MATRIX,=,,,,,,Tclin,Homo sapiens,HGNC:3236
cabozantinib,4715,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.65,,IC50,Inhibition of EGFR (unknown origin) by HTRF method,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
ridaforolimus,4778,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,9.699,,IC50,"Measured as dose-dependent inhibition of phosphorylation of ribosomal protein S6, a signaling protein downstream of mTOR",SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/21482695,https://pubmed.ncbi.nlm.nih.gov/21482695,INHIBITOR,Tclin,Homo sapiens,HGNC:3942
ibrutinib,4810,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.25,,IC50,Inhibition of ErbB1 relative to control,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
florbetaben F18,4818,Amyloid beta A4 protein,Unclassified,P05067,APP,A4_HUMAN,8.65,,Ki,,CHEMBL,=,,,,,,,Homo sapiens,HGNC:620
naloxegol,4832,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,,,,Mechanism of Action,DRUG LABEL,,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
levomilnacipran,4864,Glutamate NMDA receptor,Ion channel,P35439|Q00959|Q00960|Q00961|Q62645|Q8VHN2|Q9R1M7,Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a,NMDZ1_RAT|NMDE1_RAT|NMDE2_RAT|NMDE3_RAT|NMDE4_RAT|NMD3B_RAT|NMD3A_RAT,5.2,,IC50,Binding affinity for N-methyl-D-aspartate glutamate receptor of cerebral cortical synaptic membranes from rats using [3H]MK-801 as radioligand,CHEMBL,=,,,,,,,Rattus norvegicus,RGD:2736
ceritinib,4866,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.05,,IC50,Inhibition of EGFR (unknown origin) after 60 mins,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
dexrabeprazole,4867,Fatty acid synthase,Enzyme,P49327,FASN,FAS_HUMAN,5.23,,Ki,Inhibition of purified recombinant FASN TE activity (unknown origin) using 4-MUH as substrate preincubated for 30 mins before substrate addition measured after 1 hr by fluorescence assay,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:3594
lenvatinib,4942,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.187,,IC50,in vitro kinase activity at 1uM ATP,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/17943726,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
cetuximab,4954,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.41,,Kd,,IUPHAR,=,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:3236
panitumumab,4955,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,10.3,,Kd,,IUPHAR,=,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf,AGONIST,Tclin,Homo sapiens,HGNC:3236
brentuximab vedotin,4964,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,microtubule disrupting agent auristatin E,DRUG LABEL,,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
trastuzumab emtansine,4990,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,microtubule destabilizing agent maytansine derivative,DRUG LABEL,,1.0,DRUG LABEL,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf,INHIBITOR,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
osimertinib,5062,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.824,,IC50,Inhibition of EGFR phosphorylation in double mutant cell line H1975,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/25271963,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
ixazomib,5067,Proteasome subunit beta type-1,Enzyme,P20618,PSMB1,PSB1_HUMAN,7.509,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/20160034,,INHIBITOR,Tclin,Homo sapiens,HGNC:9537
ixazomib,5067,Proteasome subunit beta type-2,Enzyme,P49721,PSMB2,PSB2_HUMAN,5.456,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/20160034,,INHIBITOR,Tclin,Homo sapiens,HGNC:9539
necitumumab,5071,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,9.49,,Kd,Binding affinity of whole IMC-11F8 IgG using BIAcore sensor technology.,IUPHAR,=,1.0,DRUG LABEL,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf,ANTIBODY BINDING,Tclin,Homo sapiens,HGNC:3236
chromic chloride,5118,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.53,,IC50,,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
brodalumab,5179,Interleukin-17 receptor,Membrane receptor,Q96F46|Q8NAC3,IL17RA|IL17RC,I17RA_HUMAN|I17RC_HUMAN,9.2,,Kd,,IUPHAR,=,1.0,SCIENTIFIC LITERATURE,,https://pubmed.ncbi.nlm.nih.gov/22455412,ANTIBODY BINDING,Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:5985
icotinib,5209,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.699,,IC50,,SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/22959248,https://pubmed.ncbi.nlm.nih.gov/22088449,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
olmutinib,5210,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.036,,IC50,HCC827 cells expressing EGFR(DEL19),SCIENTIFIC LITERATURE,=,1.0,SCIENTIFIC LITERATURE,https://pubmed.ncbi.nlm.nih.gov/27357069,https://pubmed.ncbi.nlm.nih.gov/27357069,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
naldemedine,5220,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.95,,Ki,,IUPHAR,=,1.0,DRUG LABEL,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
brigatinib,5233,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.174,,IC50,,SCIENTIFIC LITERATURE,=,,,https://pubmed.ncbi.nlm.nih.gov/27780853,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
neratinib,5252,Mitogen-activated protein kinase kinase kinase 10,Kinase,Q02779,MAP3K10,M3K10_HUMAN,5.34,,Kd,Binding constant for MLK2 kinase domain,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:6849
neratinib,5252,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,7.036,,IC50,,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/15715478,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
copanlisib,5256,Serine/threonine-protein kinase mTOR,Kinase,P42345,MTOR,MTOR_HUMAN,7.35,,IC50,,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3942
dacomitinib,5297,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,8.222,,IC50,ELISA-Based erbB Kinase Assay with 20 uM [ATP],SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/30506139,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
polatuzumab vedotin,5333,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,Mechanism of Action,UNKNOWN,,1.0,DRUG LABEL,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf,BINDING AGENT,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
brilliant Blue G,5359,Alpha-synuclein,Transporter,P37840,SNCA,SYUA_HUMAN,5.27,,IC50,Inhibition of wild type alpha-synuclein (unknown origin) aggregation expressed in Escherichia coli BL21 after 30 days by thioflavin T staining-based spectrofluorimetric analysis,CHEMBL,=,,,,,,Tchem,Homo sapiens,HGNC:11138
enfortumab vedotin,5366,Tubulin beta,Tumour-associated antigen,P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7,TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN,,,,Mechanism of Action,UNKNOWN,,1.0,DRUG LABEL,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf,BINDING AGENT,Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin|Tclin,Homo sapiens,HGNC:20778
bempedoic acid,5382,ATP-citrate synthase,Enzyme,P53396,ACLY,ACLY_HUMAN,5.69,,Ki,Inhibition of ACL by ETC-1002-CoA,SCIENTIFIC LITERATURE,=,1.0,DRUG LABEL,https://pubmed.ncbi.nlm.nih.gov/27892461,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf,INHIBITOR,Tclin,Homo sapiens,HGNC:115
selumetinib,5388,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,5.66,,Kd,Binding constant for EGFR(T790M) kinase domain,CHEMBL,=,,,,,,Tclin,Homo sapiens,HGNC:3236
tucatinib,5389,Epidermal growth factor receptor,Kinase,P00533,EGFR,EGFR_HUMAN,6.35,,IC50,Inhibition of enzyme activity in a biochemical assay.,IUPHAR,=,,,,,INHIBITOR,Tclin,Homo sapiens,HGNC:3236
oliceridine,5406,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,8.22,,Ki,Mechanism of Action,DRUG LABEL,=,1.0,DRUG LABEL,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf,AGONIST,Tclin,Homo sapiens,HGNC:8156
trilaciclib,5442,Cyclin-dependent-like kinase 5,Kinase,Q00535,CDK5,CDK5_HUMAN,5.83,,IC50,,DRUG LABEL,=,,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf,,INHIBITOR,Tchem,Homo sapiens,HGNC:1774
samidorphan,5460,Mu-type opioid receptor,GPCR,P35372,OPRM1,OPRM_HUMAN,10.28,,Ki,Possible target for the mechanism of action of the drug,DRUG LABEL,=,,,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf,,ANTAGONIST,Tclin,Homo sapiens,HGNC:8156
